Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands
Open Access
- 21 June 2004
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (3) , 310-316
- https://doi.org/10.1111/j.1365-2125.2004.02152.x
Abstract
Aim: To assess recent trends in undertreatment of hypercholesterolaemia (1998–2002).Methods: Data were obtained from the third cross‐sectional examination of the Monitoring Project on Risk Factors for Chronic Diseases (n = 4878; age 31–70 years), conducted in the Netherlands. Treatment eligibility was established according to Dutch guidelines. Data from the second examination (1993–1997) were used to assess time trends. The association between demographic variables, cardiovascular disease risk factors, drug use and lipid‐lowering medication was assessed using multivariable logistic regression.Results: Overall, 45.9%[95% confidence interval (CI) 41.4, 50.4] of respondents eligible for treatment were treated, and 17.4% (95% CI 13.9, 20.9) were both treated and controlled (1998–2002). Treatment increased significantly after 1995, showed a slight decrease in subsequent years until 2000, when treatment increased again. Subgroups less frequently treated for primary prevention included among others males [odds ratio (OR) = 0.08; 95% CI 0.03, 0.21], younger patients (OR = 0.93 per year; 95% CI 0.88, 0.98), diabetics (OR = 0.19; 95% CI 0.07, 0.56), untreated hypertensives (OR = 0.21; 95% CI 0.09, 0.49) and current smokers (OR = 0.09; 95% CI 0.03, 0.25). In secondary prevention, patients with a history of stroke were less likely to receive treatment (OR = 0.41; 95% CI 0.18, 0.94) compared with patients with a history of ischaemic heart disease.Conclusions: Treatment of hypercholesterolaemia has steadily increased over the past 10 years in the Netherlands. However, at present still less than one out of two eligible for treatment is treated, and only about one out of six is both treated and controlled.Keywords
This publication has 24 references indexed in Scilit:
- Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?Heart, 2003
- Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practicesBMJ, 2003
- Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001:change over timeEuropean Journal of Clinical Pharmacology, 2002
- Age and the Burden of Death Attributable to Diabetes in the United StatesAmerican Journal of Epidemiology, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment PatternsPreventive Medicine, 2002
- Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up StudyEpidemiology, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional surveyBMJ, 2000
- Growth in use of statins after trials is not targeted to most appropriate patientsClinical Pharmacology & Therapeutics, 2000